Fetal macrosomia is described as a medical condition in which baby is significantly larger than average before birth. The average birth weight of babies is seven pounds. The possible signs and symptoms of macrosomia are large fundal height and excessive amniotic fluid (polyhydramnios). The most common causes of macrosomia are genetic, maternal conditions such as diabetes or obesity, jaundice, respiratory distress, exceptionally the infant might have some medical conditions which may be responsible for accelerating the fetal growth. Some major risk factors related to macrosomia are injury to new born such as shoulder dystocia.
The babies with macrosomia have a birth weight more than 8 pounds, 13 ounces (4,000 grams). Approximately 9% of babies born weigh more than 8 pounds, 13 ounces. Fetal macrosomia occurs in around 10% of all pregnancies in the US. Increasing occurrence of macrosomia is a key factor for market growth. Increasing awareness play an important role in the growth of this market. Macrosomia birth may leads to various medical complications.
Increasing demand of accurate diagnosis and treatment from emerging markets of Asia and South America is major driving force of this market. Healthcare sector is rapidly changing in this region due to various factors such as technological advancement and increasing healthcare expenditure.
Pharmaceutical companies, medical research centers and hospitals are working on effective cure for fetal macrosomia by investing large amount of money and resources for R&D. Introduction of advanced diagnostic tools are another important factor for the market growth.
The global fetal macrosomia market is growing moderately and is expected to continue its growth during the forecast period. Global fetal macrosomia market is expected to grow at the CAGR of ~4.1% during the forecast period and is estimated to reach USD 3034.1 million by 2023.
Key players for global fetal macrosomia market:
Some of the key players in this market are: Carestream Health (US), Esaote SpA (Italy), Fonar Corporation (US), Fujifilm Holdings Corporation (Japan), GE Healthcare (UK), Hitachi Medical Corporation (Japan), Hologic, Inc. (US), Philips Healthcare (Netherlands), Samsung Medison Co. Ltd (Republic of Korea), Shimadzu Corporation (Japan), Siemens Healthcare (Germany), Toshiba Corporation (Japan),) and others.
Segments:
Global Fetal macrosomia market has been segmented on the basis of diagnosis which comprise of ultrasound, antenatal testing, and others. Ultrasound is further sub-segmented into standard ultrasound, transvaginal scan, fetal echocardiography, 3-d ultrasound, dynamic 3-d ultrasound, and others. Antenatal testing is further sub-segmented into blood and urine tests, amniocentesis, chorionic villus sampling, and others.
On the basis of treatments, the market has been segmented into medical care, surgical care, and others. Surgical Care is sub-segmented into cesarean delivery, and others.
On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.
Request Customization
Get a Sample
Get a Sample
Request Customization